Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Proteomic profiling of plasma extracellular vesicles reveals a therapeutically targetable liver-heart axis in cardiac transplantation
Shiyu Dai, Wei Zhou, Fangyu Chen, Huanyu Zhang, Zhenchun Ji, Xuejing Zong, Wanruo Zhang, Jie Hu, Shumin Jiang, Fei Wang, Zhenya Shen
Shiyu Dai, Wei Zhou, Fangyu Chen, Huanyu Zhang, Zhenchun Ji, Xuejing Zong, Wanruo Zhang, Jie Hu, Shumin Jiang, Fei Wang, Zhenya Shen
View: Text | PDF
Research Article Cardiology Immunology

Proteomic profiling of plasma extracellular vesicles reveals a therapeutically targetable liver-heart axis in cardiac transplantation

  • Text
  • PDF
Abstract

Extracellular vesicle–mediated interorgan communication represents a promising frontier in transplant immunology; however, its role in cardiac allograft rejection remains poorly characterized. We performed proteomic profiling of plasma-derived extracellular vesicles in a rat heterotopic heart transplantation model and identified a distinct liver-predominant protein signature during acute rejection, with antithrombin III (ATIII) emerging as a top candidate. Functional validation revealed that pharmacological extracellular vesicle inhibition intensified systemic and intragraft inflammation, whereas adeno-associated virus–mediated silencing of hepatic ATIII directly accelerated allograft rejection. Conversely, adeno-associated virus–mediated hepatocyte-specific ATIII overexpression attenuated rejection pathology, reduced immune cell recruitment, and markedly prolonged median graft survival. This protective effect was achieved without evidence of coagulopathic complications, indicating an immunomodulatory mechanism beyond ATIII’s canonical anticoagulant function. Mechanistically, ATIII overexpression was associated with upregulation of heme oxygenase-1 (HO-1) in the liver and suppression of proinflammatory cytokine expression in the graft. These findings highlight hepatocyte-derived extracellular vesicles as important mediators of a liver-heart signaling axis in transplant rejection and further implicate the protein ATIII as a contributor to this axis. Our study reveals a therapeutically targetable liver-heart signaling axis in transplant rejection, whereby enhancing liver-derived ATIII or its downstream pathways (such as HO-1) could attenuate acute cardiac allograft rejection.

Authors

Shiyu Dai, Wei Zhou, Fangyu Chen, Huanyu Zhang, Zhenchun Ji, Xuejing Zong, Wanruo Zhang, Jie Hu, Shumin Jiang, Fei Wang, Zhenya Shen

×

Figure 6

Genetic silencing of hepatic ATIII accelerates cardiac allograft rejection and intensifies immune infiltration.

Options: View larger image (or click on image) Download as PowerPoint
Genetic silencing of hepatic ATIII accelerates cardiac allograft rejecti...
(A) Experimental workflow. Lewis rats were i.v. injected with AAV-shSerpinc1 or AAV-shCtrl to induce hepatocyte-specific ATIII knockdown 4 weeks before transplantation. Endpoints included graft survival and mechanistic assessment at postoperative day 5. (B) Kaplan-Meier curves comparing allograft survival between groups (log-rank test; shCtrl, n = 7; shSerpinc1, n = 7). (C and D) Hepatic ATIII knockdown verified by representative Western blots (C, 3 rats per group shown) and quantitative analysis (D, n = 6 biological replicates). Blots are representative of 2 independent experiments. (E) Histological and IHC assessment. Representative H&E, CD4, CD8, and CD68 IHC staining of cardiac allografts from the biological replicates. Scale bar: 50 μm. (F) Graft inflammatory profile. Relative mRNA levels of proinflammatory cytokines (Il1b, Tnfa, Il6, Ifng), chemokines (Cxcl9, Cxcl10), cytotoxic molecules (Prf1, Gzmb), and regulatory factors (Tgfb1, Il10) in cardiac allografts. (G and H) Systemic immune monitoring. Peripheral WBC counts (G) and lymphocyte counts (H) in recipient rats. Data are presented as mean ± SEM. Sample sizes for C–H: shCtrl, n = 6; shSerpinc1, n = 6 biological replicates. Statistical significance in F for Il6 and Cxcl10 was determined by 2-tailed Welch’s t test due to unequal variance; all other comparisons in D and F–H were analyzed by unpaired 2-tailed Student’s t test. *P < 0.05, ns, not significant.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts